CHENGDU OLYMVAX BIOPHARMACEUTICALS INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.51 CNY | -2.30% |
|
-1.16% | -46.14% |
| May. 16 | Olymvax Biopharma's Flu Vaccine Gets China Nod for Clinical Trials | MT |
| Apr. 25 | Chengdu Olymvax Biopharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Chengdu Olymvax Biopharmaceuticals Inc is a China-based biopharmaceutical company mainly engaged in the research, development, production and sales of human vaccines. The Company's products mainly include adsorbed tetanus vaccine, Hib conjugate vaccine and tetanus toxoid concentrate stock solution. The Company's main customers are center for disease control and prevention (CDC) customers.
Sector
Pharmaceuticals
Calendar
2024-08-15
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
8.51
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -46.14% | 489M | |
| -1.62% | 89.22B | |
| +1.32% | 40.49B | |
| -15.73% | 32.79B | |
| +64.13% | 26.23B | |
| -21.28% | 14.52B | |
| -8.50% | 13.09B | |
| -44.07% | 11.6B | |
| -13.06% | 11.5B | |
| +4.94% | 8.82B |
- Stock Market
- Equities
- 688319 Stock
- News Chengdu Olymvax Biopharmaceuticals Inc.
- Olymvax Biopharmaceuticals Grants Keyuan Xinhai Marketing Rights for Meningococcal Vaccines
